Tag Archives: NIH

Sequestration: How Big a Hit for FDA, Research and Pharma?

The greatly feared federal budget sequestration mandate went into effect March 1, and, initially, the impact was fairly muted. The stock market soared, employment rose and government workers continued on their jobs. Federal agencies, including the Food and Drug Administration (FDA), launched initiatives to comply with the mandated 5% across-the-board cut in spending (in reality […]
Posted in FDA, healthcare, leadership, Legal, R&D | Also tagged , , , , , , | Leave a comment

Taxpayers and Embryonic Stem Cell Research

Last Friday, an appellate court upheld an earlier judgment allowing government to fund embryonic stem cell research for the development of new therapies. Biotechs and advocacy groups cheered the decision but uncertainty remains, in large part due to the possibility of a Romney administration in the White House.
Posted in Biotech, Legal, R&D, Regulatory, Strategy, Technology | Also tagged , , , , , , | 1 Comment

Biomedical Innovation in Trouble

The time and cost of developing new drugs are rising, venture capitalists make no return on investments in biopharma R&D, and other countries are boosting support in this area while U.S. policy makers propose funding cuts for the National Institutes of Health (NIH). This bleak picture of the “state of biomedical innovation” was painted by […]
Posted in Biotech, FDA, healthcare, leadership, R&D, Technology | Also tagged , , , , | 3 Comments

Industry Optimism for Advancing TB Research

Scientists optimistic new combination regimens will improve TB treatment and reduce drug resistance, writes Jill Wechsler, Pharm Exec‘s Washington Editor. In honor of World TB Day March 24, research organizations and international health agencies announced important advances in the development of new therapies for stemming the spread of increasingly lethal tuberculosis strains. Each year, nearly […]
Posted in FDA, Global, healthcare, Op-Ed | Also tagged , , | Leave a comment

Rare Disease Day: Spotlight on Solidarity

Patients, policymakers and pharmaceutical companies are uniting around rare diseases on the rarest of calendar days, presaging a leap forward in health outcomes and business opportunities. Aligning humanistic objectives with business incentives is often the sine qua non of effective community activism. This year’s Rare Disease Day – hosted in the US by the National […]
Posted in Events, FDA, Global, healthcare, leadership, Patient Communication, patient education, social media, Strategy | Also tagged , , , , , , | Leave a comment
  • Categories

  • Meta